
ANTX Stock Forecast & Price Target
ANTX Analyst Ratings
Bulls say
AN2 Therapeutics Inc. is positioned favorably in the biopharmaceutical market due to the promising safety and tolerability profile of its lead candidate, epetraborole, which demonstrated mild and reversible reductions in hemoglobin during Phase 2 trials. The drug shows potential for significant clinical impact on quality of life for patients suffering from non-tuberculous mycobacterial (NTM) infections, particularly with its ability to reduce cough frequency and intensity, a common debilitating symptom in these patients. Additionally, the company’s positive outlook is bolstered by strong pre-clinical data indicating epetraborole's effectiveness against more challenging NTM strains, suggesting a potential expansion of its therapeutic application in treating these serious infections.
Bears say
AN2 Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to disappointing clinical results from its lead candidate, epetraborole, and a historical pattern of financial losses without a clear path to profitability. The company is also exposed to considerable risks associated with its development pipeline, including potential failures to meet efficacy and safety endpoints, which could jeopardize regulatory approval and commercialization efforts. Additionally, AN2 faces uncertainties related to market conditions, emerging competition, and the possible impact of litigation on its market exclusivity, all of which heighten the financial risks associated with its investments in novel therapeutics.
This aggregate rating is based on analysts' research of AN2 Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ANTX Analyst Forecast & Price Prediction
Start investing in ANTX
Order type
Buy in
Order amount
Est. shares
0 shares